Market research
ETNB 89bio Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 30.375
- Dividend yield
- Not available
- Beta
- 1.26
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US2825591033
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 30.375
- Dividend yield
- Not available
- Beta
- 1.26
About
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ETNB discussion.
5 years, 4 months ago
89bio, Inc is currently in a long term downtrend where the price is trading 31.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
89bio, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 34.8% to $-13M since the same quarter in the previous year.
Finally, its free cash flow fell by 24.8% to $-14M since the same quarter in the previous year.
Based on the above factors, 89bio, Inc gets an overall score of 2/5.